Related Experiment Video
Updated: Jul 15, 2026

07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Small Nucleolar RNAs (snoRNAs) in Cancer: From Biogenesis to Clinical Potential
Han Zhang1, Chunli He1, Dan Chen1
1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Oncotargets and Therapy
|July 14, 2026
Summary
Small nucleolar RNAs (snoRNAs) and their products are crucial in cancer. Dysregulation of these regulatory RNAs drives tumor progression and offers potential for non-invasive cancer diagnostics.
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Research
Background:
- Small nucleolar RNAs (snoRNAs) are key regulators of ribosomal RNA processing and translation.
- They influence epigenetic modifications through protein interactions and can be processed into piwi-interacting RNAs (piRNAs) and snoRNA-derived fragments (sdRNAs).
- Aberrant expression of snoRNAs and their products is common in tumors, contributing to oncogenic functions.
Purpose of the Study:
- To review snoRNA biogenesis and mechanisms of dysregulation in cancer.
- To elucidate the impact of aberrant snoRNAs on tumorigenesis and cancer progression.
- To highlight clinically significant snoRNAs for diagnostic and therapeutic applications.
Main Methods:
- Literature review of snoRNA biogenesis pathways.
- Analysis of DNA and RNA alterations leading to snoRNA dysregulation in malignancies.
- Examination of oncogenic mechanisms driven by aberrant snoRNAs.
Main Results:
- SnoRNA dysregulation arises from DNA alterations (mutations, chromosomal aberrations) and RNA-level disruptions (epigenetic modifications, degradation, trafficking).
- Dysregulated snoRNAs promote cancer hallmarks like proliferation, invasion, angiogenesis, and immune evasion via epigenetic remodeling and ceRNA networks.
- Tumor-associated snoRNAs in body fluids show promise as non-invasive biomarkers for early cancer detection and prognosis.
Conclusions:
- SnoRNAs and their derived small RNAs play critical roles in cancer development and progression.
- Understanding snoRNA dysregulation mechanisms is vital for developing novel cancer therapies.
- Aberrant snoRNAs represent promising biomarkers for early cancer diagnosis and predicting patient outcomes.
Related Concept Videos
The Nucleolus
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Ribosomal RNA Synthesis
Ribosome synthesis is a highly complex and coordinated process involving more than 200 assembly factors. The synthesis and processing of ribosomal components occurs not only in the nucleolus but also in the nucleoplasm and the cytoplasm of eukaryotic cells.
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
Ribosome biogenesis begins with the synthesis of 5S and 45S pre-rRNAs by distinct RNA polymerases. The primary transcripts are extensively processed and modified before they are bound and folded by ribosomal proteins and assembly factors,...
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
